# Johnson & Johnson Q2 Results May Exceed Expectations Despite Stelara challenges, company profitability is rising. - **Source:** [Breaking News on Seeking Alpha](https://brifing.si/source/9a596115-e1cc-45e7-b5ba-070be9ea2998) - **Published:** 2026-07-14 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/fe0fc6da-9e2e-48fb-ae4c-11035a1aa071 ## Johnson & Johnson Q2 Expectations Healthcare giant Johnson & Johnson is expected to report second-quarter results on July 15 that surpass analyst predictions. Wall Street anticipates earnings per share of $2.85. ## Stelara Impact Despite reduced patent protection for Stelara, a key revenue driver, Johnson & Johnson's overall performance is expected to remain strong. Growth in other products may offset this decline. ## Annual Growth Analysts project a year-over-year earnings increase of approximately 3%, highlighting the resilience of Johnson & Johnson's diversified product portfolio. ## Wall Street Predictions Financial analysts emphasize the company's robust performance, particularly noting sustainable growth in its pharmaceutical and medical device divisions. ## Market Reaction The anticipated positive results are expected to boost confidence in Johnson & Johnson shares. Investors appreciate the company's long-term growth strategies. ## Industry Position Johnson & Johnson's expected performance reinforces its leadership in the healthcare sector. Innovative products and global presence maintain its competitive edge. ## Sources covering this story - https://seekingalpha.com/news/4613688-johnson-johnson-analysts-see-upbeat-q2-print-despite-stelara-headwinds?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._